Morgan Stanley Maintains Overweight on Biogen, Lowers Price Target to $361
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Biogen (NASDAQ:BIIB) but has lowered the price target from $381 to $361.
October 11, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on Biogen but lowered the price target from $381 to $361.
The news is directly related to Biogen and is likely to influence investor sentiment. While the Overweight rating is positive, the reduction in price target may have a neutral to slightly negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100